Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects by Diao, Guoqing et al.
Statistical design of noninferiority multiple region clinical trials 
to assess global and consistent treatment effects
Guoqing Diaoa, Donglin Zengb, Joseph G. Ibrahimb, Alan Rongc, Oliver Leec, Kathy Zhangc, 
and Qingxia Chend
aDepartment of Statistics, George Mason University, Fairfax, Virginia, USA
bDepartment of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North 
Carolina, USA
cAmgen Inc., Thousand Oaks, California, USA
dDepartment of Biostatistics, Vanderbilt University, Nashville, Tennessee, USA
Abstract
Noninferiority multiregional clinical trials (MRCTs) have recently received increasing attention in 
drug development. While a major goal in an MRCT is to estimate the global treatment effect, it is 
also important to assess the consistency of treatment effects across multiple regions. In this paper, 
we propose an intuitive definition of consistency of noninferior treatment effects across regions 
under the random-effects modeling framework. Specifically, we quantify the consistency of 
treatment effects by the percentage of regions that meet a predefined treatment margin. This new 
approach enables us to achieve both goals in one modeling framework. We propose to use a signed 
likelihood ratio test for testing the global treatment effect and the consistency of noninferior 
treatment effects. In addition, we provide guidelines for the allocation rule to achieve optimal 
power for testing consistency among multiple regions. Extensive simulation studies are conducted 
to examine the performance of the proposed methodology. An application to a real data example is 
provided.
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1. Introduction
Drug development in recent years has seen the increased popularity of multiregional clinical 
trials (MRCTs). By including relevant regions in one protocol, MRCTs, when well 
conducted, can simultaneously achieve two important goals, per the International 
Conference on Harmonization (ICH) E5 and ICH E17 (ICHE17) guidelines (ICH1998). 
First, an MRCT can provide a global estimate of treatment effect by combining data from 
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different regions. Secondly, it can provide the needed regional information to bridge the 
global conclusion to each region or between different regions (Hung et al., 2010). However, 
the key to achieving these goals rests mainly on the consistency of the treatment effects 
across different regions. If the treatment effects are similar across regions, the global 
treatment effect estimate should provide a more precise estimate for the treatment effect 
while regional estimates should provide adequate evidence for internal bridging. Otherwise, 
reasons for regional differences need to be explored and additional bridging studies may be 
necessary.
For each MRCT, evaluation of treatment consistency usually covers both the global 
consistency and the regional-specific consistency. Although regional-specific consistency 
(one region vs. the rest, or one region vs. another) is relevant for regional approval, global 
consistency (whether treatment effects are similar across all regions) is more essential to 
warrant the validity of the primary study conclusion. Several regional agencies, including the 
Committee for Medicinal Products for Human Use Committee for Medicinal Products for 
Human Use (CHMP) (2009) and Ministry of Health, Labour and Welfare of Japan (2007), 
have issued guidance on the assessment of treatment consistency in MRCTs. More recently, 
Quan et al. (2010), Chen et al. (2010), and Shih and Quan (2013) described a variety of 
methods for evaluating the global and/or regional treatment consistency. A summary of the 
regulatory requirements and detailed discussion of these methods are provided in the book 
Design and Analysis of Bridging Studies (Liu et al., 2013).
Most MRCTs assume treatment consistency when designing the trial. But in reality, regional 
treatment effects differ due to potential intrinsic and extrinsic factors as classified by ICH E5 
Guideline such as ethnics, culture, diet, genetics, and environment. See Chapter 1 of Design 
and Analysis of Bridging Studies (Liu et al., 2013) for a detailed discussion. A fixed effects 
model as well as a random effects model can provide estimates on both overall and regional 
treatment effects. The question as to which model is more appropriate often remains open. 
There is however a growing recognition that a random effects model may provide more 
robust assessments in MRCTs due to its capacity to incorporate the additional between-
region variability in the estimation procedure. Furthermore, a fixed-effects model may 
involve many parameters when there are many regions. See Hung et al. (2010) for a 
discussion on how different models can impact study design on power and sample size, and 
Quan et al. (2013) on how to use the random effects model to estimate the overall and 
regional treatment effect. As active treatments are approved and available to patients, 
placebo controlled studies for the development of additional treatments may no longer be 
ethical.
As pointed out in Section 3.5.2 by Shih and Quan (2013), most of the methods discussed so 
far have focused consistency on superiority trials hence may not be directly applicable to 
noninferiority trials. A noninferiority study compares an investigational drug with an active 
control with the objective of demonstrating that the difference between the two is within an 
acceptable limit. The experimental drug may have nonefficacious benefits such as reduced 
toxicities, lower cost, or route of administration. Final guidance on the conduct of non-
inferiority clinical trials was provided by FDA (2016). Methods to define the noninferiority 
margin and critical assumptions of noninferiority studies are all described in the FDA 
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document. There is limited work on assessing consistency in a noninferiority MRCT. 
Proposed methods for non-inferiority trials include shifted quantitative and qualitative 
treatment by region interaction tests (Wiens and Heyse, 2003; Hsieh and Liu, 2013) and a 
simultaneous test by Quan and Shih (2002) that jointly tests all regions against region-
specific noninferiority margins. Essentially all these methods are based on fixed effect 
models.
A motivating example was a noninferiority MRCT on patients with colorectal cancer (CRC), 
which is the fourth-leading cause of cancer-related deaths worldwide. It has been known that 
the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab (a 
chimeric IgG1 antibody) and panitumumab (a fully human IgG2 antibody) provide clinical 
benefit in patients with chemotherapy-refractory metastatic colorectal cancer (mCRC) in the 
monotherapy setting (Jonker et al., 2007; Van Cutsem et al., 2007). The standard of care has 
evolved since the approval of these agents, and consequently, the re-evaluation of safety and 
efficacy in this setting is important and timely. The randomized, double-blind, phase 3 
ASPECCT study (A Study of Panitumumab Efficacy and Safety Compared to Cetuximab) is 
the first head-to-head comparison of overall survival (OS) benefit of panitumumab and 
cetuximab in chemotherapy-refractory wild-type Kirsten rat sarcoma viral oncogene 
homolog exon 2 mCRC (Price et al., 2014). ASPECCT, which enrolled patients worldwide, 
is the largest prospective direct comparison of anti-EGFR therapies in mCRC, and is among 
the largest head-to-head comparisons of anticancer biologic agents in mCRC. The study was 
conducted in 27 countries in North and South America, Europe, Asia, Africa, and Australia. 
Four countries with sample sizes ≤ 5 were excluded from the analysis. Crossover between 
panitumumab/cetuximab was not permitted during the study treatment period. Patients were 
followed up for OS for 24 months after randomization of the last patient. Given the similar 
mechanisms of action, ASPECCT is a noninferiority study designed to demonstrate that 
panitumumab retains ≥ 50% of the OS treatment effect of cetuximab versus best supportive 
care (BSC). The predicted effect of cetuximab versus BSC on OS was based on the CO.17 
study (Karapetis et al., 2008) (hazard ratio [HR]= 0.55; 95% CI, 0.41 0.74). A thousand 
patients were enrolled to achieve 90% power with a one-sided α = 0.025 for the OS 
inferiority null hypothesis.
In this paper, we propose a statistical design for an MRCT in order to evaluate the 
noninferiority of an experimental drug in multiple regions and to assess consistency of the 
treatment effects across regions. We provide a new definition of consistency of noninferior 
treatment effects across multiple regions under the random effects modeling framework. We 
then propose to use the signed likelihood ratio test (LRT) for testing consistency and derive 
an optimal allocation rule to maximize the power. Extensive simulation studies are carried 
out to examine the performance of the proposed methodology. An application to a real data 
example is provided. The rest of this paper is organized as follows. In Section 2, we describe 
the proposed methodology to define and test consistency of treatment effects in a 
noninferiority MRCT. Extensive simulations studies are presented in Section 3 to examine 
the finite sample properties of the proposed methodology. In Section 4, we illustrate the new 
methods through an application to the motivating ASPECCT study. We conclude with a brief 
discussion in Section 5.
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2. Methods
2.1. Definition of consistency
In this section, we provide an intuitive and new definition of consistency of noninferior 
treatment effects across regions. We focus on global consistency because it is most 
important. Noninferiority MRCTs, with their usual large study size, often enroll patients in 
large number of regions. Unless specifically committed, sample sizes in most regions (if not 
all) in noninferiority MRCTs do not warrant an independent region-specific test of 
noninferiority with reasonable power. Therefore, almost all regulatory agencies will rely 
heavily on strength of the global consistency of the data to extrapolate the overall study 
conclusion to their specific regions for drug approval.
Consider L regions and let βl denote the log-hazard ratio for the lth region, l = 1,…, L. Since 
βl varies from region to region, a reasonable model to quantify this variability is to assume a 
random effects model:
(1)
where the ul’s are i.i.d N(0, σ2) random variables and σ2 characterizes the variability across 
the regions. This random-effects model framework allows one to model heterogeneity 
among the patient population across different regions. A value of 0 for σ2 implies that there 
is no treatment difference across different regions. This kind of mixed effects model has 
been extensively used in different settings such as in meta-analysis.
In model (1), β represents the overall treatment effect across regions. Therefore, a 
noninferiority MRCT involves testing H0g : β − β0 > M, where β0 is the effect of an active 
control and M is the specified margin. In practice, we usually set β0 = 0. Rejecting H0g will 
provide evidence to declare that the log-hazard of the experimental drug is at most M larger 
than the log-hazard of the active control. In an MRCT, in addition to testing the treatment 
effect, another important objective is to assess the global consistency across regions. Here 
we propose an intuitive definition for global consistency using a probabilistic approach to 
accommodate the usual large number of regions involved in noninferiority MRCTs. 
Assuming all regional treatment effects come from the same underlying distribution, we 
define consistency based on the percent of regions among all regions that indeed reach 
noninferiority. Consistency is achieved when the percentage of those regions surpasses a 
prespecified threshold. Notice this definition is different from the concept of treatment 
similarity proposed by Liu et al. (2009) for superiority trials although both involve 
noninferiority hypothesis testing. Under this definition, consistency is achieved as long as 
the treatment is noninferior to the active control in the majority of the regions even if the 
regional effects are very different.
For the above consistency definition, one quantity for assessing the majority of noninferior 
treatment effects is P(βl − β0 ≤ M) where βl is given in model (1). Therefore, if this 
probability is larger than a prespecified proportion p (say, 80%), then this means that at least 
p × 100% of the regions would have noninferior treatment effects. Since P (βl − β0 ≤ M) = Φ 
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{(β0 + M − β)/σ} where Φ(.) is the cumulative distribution function of the standard normal 
distribution, consistency thus holds if β − β0 ≤ M − σ Φ−1(p), where Φ−1(p) is the 100pth 
percentile of the standard normal distribution. In other words, the null hypothesis we wish to 
reject is:
The above definition of consistency enables us to test both the global treatment effect and 
the consistency of treatment effects across multiple regions with one test and one common 
noninferiority margin. Note that the null hypothesis for testing the global treatment effect is:
and Φ−1(0.5) = 0. Therefore, to test the global treatment effect is equivalent to testing that 
50% of the regions have noninferior treatment effects by setting p = 0.50. If the margin M is 
deemed to be too rigorous, we can certainly use a separate test with a different (and perhaps 
more relaxed) margin to test the hypothesis for global consistency.
2.2. Signed (LRT) approach
In this section, we describe a signed LRT (Barndorff-Nielsen, 1986) for testing the 
consistency of noninferior treatment effects defined in the previous section 2.1. Without loss 
of generality, we fit a survival model for each region separately and obtain the parameter 
estimates , l = 1,…, L. The estimated variance of based on the data from the lth region is 
, l = 1,…, L. We then fit the following linear mixed model:
(2)
where ul ~ N(0, σ2) and . We assume  is known, where  is related to 
disease prevalence of each specific region (Kalbfleisch and Prentice, 2011, Chapter 5.7) and 
is often available to investigators. We can maximize the following log-likelihood to obtain 
the maximum likelihood estimators (MLEs) of β and σ, denoted by  and :
where C is a constant.
Recall that the null hypothesis H0c (i.e., p × 100% of the regions have noninferior treatment 
effects) for testing consistency is given by:
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where βl = β + ul. We can rewrite the above null hypothesis as:
where γ = β + σ Φ−1(p). Letting γ0 = β0 + M, the alternative hypothesis H1b is given by:
We propose to use a profile likelihood approach. The log-likelihood of the unknown 
parameters θ = (γ, σ2) is given by:
We denote the MLE of θ under the null hypothesis H0b and the alternative hypothesis H1b by 
 and , respectively. The LRT statistic for testing H0b is given by:
Under the null hypothesis, W asymptotically follows a  distribution. Since we have a one-
sided alternative hypothesis, we consider the signed likelihood ratio test statistic (Barndorff-
Nielsen, 1986):
where sign (x) = I(x > 0) − I(x < 0) and I(·) is the indicator function. Under H0b, RMLE 
asymptotically follows a standard normal distribution and we reject the null hypothesis for 
small values of RMLE.
It is known that the MLE of σ2 is negatively biased especially when the sample size is small. 
Alternatively, we can obtain the restricted maximum likelihood (REML) estimator of θ by 
maximizing the restricted log-likelihood:
Similarly, we can calculate LRT statistic using the REML estimators, leading to:
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where  and  are the REML estimators under the null and alternative hypotheses, 
respectively. The corresponding signed LRT statistic is defined as:
where  is the REML estimator of γ under H1b.
Both signed LRT statistics RMLE and RREML have the same asymptotic standard normal 
distribution. However, the test statistic RREML based on the REML estimators is expected to 
perform better than RMLE with a small sample size, which is typical in multiple region 
clinical trials. We use the routine optim() in R (R Core Team, 2013) to maximize the log-
likelihood and the restricted log-likelihood. The proposed signed LRT tests have been 
implemented in an R package, which is freely available upon request.
2.3. Optimal allocation
In this section, we provide a procedure to allocate patients to achieve optimal power for 
testing the consistency among multiple regions in a noninferiority clinical trial. Let πl be the 
proportion of subjects in the lth region, l = 1,…, L. We propose to minimize the limiting 
variance of  for given p, vl, l = 1,…, L, and the total sample size . By 
inverting the Fisher information matrix, we can show that:
where nl = Nπl, l = 1,…, L. We minimize the above variance under the constraint 
 by using the quasi-Newton algorithm. It is worth noting that in order to obtain 
the above allocation rule, one needs to specify the values of σ2, p, vl, l = 1,…, L and the total 
sample size N.
2.4. A special case
In this section, we consider a special case under which the within region variances (vl’s) are 
assumed to be the same, i.e., v1 = ⋯ = vL = v. In this case, it can be shown that the equal 
allocation rule is optimal. In fact, we can show that the minimizer of:
is π1 = ⋯ = πL = 1/L, l = 1,…, L.
Define . Under regularity conditions and assuming σ > 0, we can show that:
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in distribution as L → ∞. Therefore, when γ − γ0 = L−1/2δ, the asymptotic local power of 
the signed LRT test at significance level α is Φ(−Zα − δ*), where:
In our experience, the above large sample approximation works reasonably well when L is 
larger than 20. We note that given L and σ2, the above asymptotic local power reaches its 
upper bound when n → ∞, under which:
3. Simulation studies
We conduct extensive simulation studies to examine the small sample performance of the 
proposed signed LRTs. We generate data from model (2) using settings similar to the 
ASPECCT study. Specifically, we set the values of L, vl, and πl, l = 1,…, L from the 
ASPECCT study as presented in Table 1, where each of the 23 countries with enrollment of 
≥ 10 subjects in this study defines one specific region. We also set β0 = 0 and M = 0.15. We 
vary the total sample size N and the variance parameter σ2 such that N = j × 575, j = 1,…, 4, 
and σ = k × 0.1345, k = 1,…, 4. Here the case of N = 1150 and σ = 0.269 corresponds to the 
setting obtained from the ASPECCT study. Note that while the null value of γ is fixed, 
different values of σ lead to different null values of β. Therefore, we vary the values of β as 
follows:
The null values of β for testing H0b : P (βl − β0 ≤ M) = 0.8 corresponding to σ = k × 0.1345, 
k = 1,…,4 are 0.0368, −0.0764, −0.1896, and −0.3028, respectively. All simulation results 
are based on 10,000 replicates.
To examine the impact of the total sample size on the power of the test, we consider the case 
when β = β0 + M − 2.69 × Φ−1 (0.8)/4, which yields reasonable powers for comparison. 
Figure 2 displays the powers of the signed LRT using the REML estimators in this case. As 
expected, the power increases as n increases. However, the rate of the increment of the 
power is small especially when σ is large.
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In the second set of simulation studies, we examine the performance of the proposed 
allocation rule and compare it with the allocation rule in the ASPECCT study and the equal 
allocation rule. We consider the same simulation setting as above. Figure 3 presents the type 
I error rates and powers of the signed LRT using the REML estimators for testing H0b : P (βl 
− β0 ≤ M) = 0.7. In all cases, the proposed allocation rule performs as well as or outperforms 
the equal allocation rule and the original allocation rule in the ASPECCT study.
4. The ASPECCT study
We apply the proposed signed LRTs to the ASPECCT study. Four regions with five or less 
patients were excluded from the analysis. Table 1 presents the data from this study including 
the log-hazard ratio estimates , standard error estimates , sample sizes nl, number of 
events dl, and , l = 1,…, 23. We note that the country level data for the ASPECCT study 
has been modified slightly since the study is still ongoing.
We analyze the data and obtain the MLEs and REML estimators of β and σ at 
 and . We apply the proposed signed 
LRT tests to the real data and consider four scenarios for the margin, M = 0.151, 0.201, 
0.251, and 0.301. We also vary p from 0.5 to 0.90. Table 2 presents the p-values of the tests 
using the MLEs and the REML estimators. For M ≤ 0.251, no significant results were 
detected for either method except when p = 0.5, under which the tests are equivalent to 
testing the overall noninferior effect of the drug because Φ−1(0.5) = 0. When M = 0.301, 
there is strong evidence that at least 70% of the regions have noninferior treatment effects. 
Note that the MLE of σ is negatively biased leading to a smaller estimator of γ compared to 
γREML and therefore, the signed LRT using MLEs tends to have smaller p-values than the 
signed LRT using the REML estimators.
We also perform a residual analysis to check the goodness-of-fit of the model to the 
ASPECCT data. We calculate the fitted values of the random effects as:
and:
Define . It can be shown that . 
Therefore, the standardized predictors of the random effects (ul’s) are given by:
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where . Figure 4 presents the histograms 
and normal Q–Q plots of . The observed data points are close to a straight line with 
intercept 0 and slope 1, suggesting a good fit of the model to the data.
5. Discussion
In this paper, we propose an intuitive definition of consistency quantified by the percentage 
of regions with noninferior treatment effects. Under this definition, the treatment effects are 
consistent if a prespecified percentage of regions have noninferior treatment effects even if 
the treatment effects are very different. It is worth to note that it is subjective to select the 
threshold and future discussion on this topic is needed. Alternatively, we can define 
consistency such that the treatment effects across regions are similar to each other. This 
definition requires that the treatment effects should not differ much from region to region. 
For this consistency definition, one quantity for assessing the variability of the treatment 
effects across regions is the so-called coefficient of variation , which 
describes how different region effects vary with respect to the whole population average 
deviation from β0. This quantity has been popularly used in assessing measurement errors in 
biomarkers. Therefore, if CV is less than a prespecified threshold c0 (say, 20%), we would 
then conclude that consistency is obtained. In other words, we will declare success of an 
MRCT if β − β0 ≤ M and CV ≤ c0, i.e., β − β0 ≤ M and . This implies that the 
null hypothesis is:
Let  and  be the MLEs or the REMLs estimator from model (2). Then we reject H0c if:
for some constants c1 and c2 which will be determined by joint distribution of  under 
. As a referee pointed out, since the threshold c0 has some subjectivity, then, similar to 
the overall noninferiority margin, the threshold should also be discussed with regulators.
Based on the definition of consistency in Section 2, consistent noninferior treatment effects 
across regions imply global noninferior treatment effects. Therefore, one may first test 
whether there is significant global noninferior treatment effect and then test for the 
consistency of noninferior treatment effects across regions given that the global noninferior 
treatment effect is significant. To control the overall type I error of the sequential test, we 
determine critical values c1 and c2 such that:
where M1 and M2 are the margins for testing the global noninferior drug effect and the 
consistency of noninferior treatment effects across regions, respectively. Note that we can 
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use more stringent margins for assessing a global treatment effect compared to assessing the 
consistency of treatment effects across regions. This methodology is the subject of future 
work.
In this paper, we have used a unified margin to assess the global consistency based on the 
definition in Section 2. Research is underway to expand this method to handle region-
specific consistency margins (in this case Ml for l = 1,…, L). However, the use of region-
specific margins for global consistency should be performed with caution in MRCTs (Tsong 
and Tsou, 2013). Defining the region-specific margins per FDA Guidelines (FDA, 2016) 
requires information on the magnitude and variability of the estimated control treatment 
effect (over placebo) in each of the regions. As discussed in Section 2, this information is 
usually unavailable hence the argument for a unified margin (which is based on the always 
available historical global control effect). Region-specific margins can be justified when 
local regulatory agencies require the assessment of regional consistency. It should be noted 
that regional consistency is more meaningful when positive conclusions on global 
noninferiority and global consistency have been reached. How to conduct these analyses 
with either a unified or a sequential approach is also the subject of future work.
This paper focused on noninferiority trials. The goal of noninferiority trial is not only to 
show that the new drug is noninferior to the active control, but also to show more 
importantly that the new drug is better than the placebo (FDA, 2016). Therefore for 
noninferiority trials, evaluating treatment effects (to ensure the new drug is better than the 
placebo) in all regions is fundamentally necessary compared with superiority trials (even if 
sample sizes may be small for some regions). Note that in the reality of drug development, 
the testing for regional consistency (i.e., are treatment effects consistent across all regions?) 
is different from the testing for overall noninferiority (i.e., is the new treatment non-inferior 
to the active control?); therefore could warrant different noninferiority margins. Based on 
our experience, noninferiority margin for regional consistency can be much less tight 
depending on the active control effect on placebo and sample sizes for each region. With a 
relaxed margin, the key for evaluating regional consistency is not whether treatment effects 
are positive, rather the treatment effects are above a predefined threshold (hence consistent) 
in most if not all regions.
Acknowledgments
The authors wish to thank the associate editor and one anonymous referee for their helpful comments that have 
greatly improved the presentation of this paper. The authors also thank Amgen’s Department of Global Biostatistics 
for providing the data on the ASPECTT trial and Dr. Chunlei Ke at Amgen for helpful discussions.
References
Barndorff-Nielsen OE. Infereni on full or partial parameters based on the standardized signed log 
likelihood ratio. Biometrika. 1986; 73:307–322.
Chen J, Quan H, Binkowitz B, Ouyang SP, Tanaka Y, Li G, Menjoge S, Ibia E. Assessing consistent 
treatment effect in a multi-regional clinical trial: A systematic review. Pharmaceutical Statistics. 
2010; 9:242–253. [PubMed: 20872623] 
Committee for Medicinal Products for Human Use (CHMP). Reflection paper on the extrapolation of 
results from clinical studies conducted outside the European Union (EU) to the EU. 2009
Diao et al. Page 11
J Biopharm Stat. Author manuscript; available in PMC 2018 March 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
FDA. Non-Inferiority Clinical Trials to Establish Effectiveness Guidance for Industry. U.S. 
Department of Health and Human Services. Food and Drug Administration, Center for Drug 
Evaluation and Research, Center for Biologics Evaluation and Research; 2016. 
Hsieh, ET-C., Liu, J-p. Interaction effects in bridging studies. In: Liu, J-pChow, S-C., Hsiao, C-F., 
editors. Design and Analysis of Bridging Studies. Boca Raton, FL: CRC Press; 2013. 
Hung H, Wang SJ, O’Neill RT. Consideration of regional difference in design and analysis of multi-
regional trials. Pharmaceutical Statistics. 2010; 9:173–178. [PubMed: 20872619] 
ICH E17. Final Concept Paper. General Principles on Planning/Designing Multi-Regional Clinical 
Trial. 2014. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E17/
E17_Final_Concept_Paper_July_2014.pdf. (accessed November 2016)
ICH, International Conference on Harmonisation. Tripartite guidance e5 ethnic factors in the 
acceptability of foreign data. The U.S. Federal Register. 1998; 83:31790–31796.
Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, 
Simes RJ, et al. Cetuximab for the treatment of colorectal cancer. New England Journal of 
Medicine. 2007; 357:2040–2048. [PubMed: 18003960] 
Kalbfleisch, JD., Prentice, RL. The Statistical Analysis of Failure Time Data. Vol. 360. Hoboken, NJ: 
John Wiley & Sons; 2011. 
Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal 
H, Shapiro JD, Robitaille S, et al. K-ras mutations and benefit from cetuximab in advanced 
colorectal cancer. New England Journal of Medicine. 2008; 359:1757–1765. [PubMed: 18946061] 
Liu, J-p, Chow, SC., Hsiao, CF. Design and Analysis of Bridging Studies. CRC Press; 2013. 
Liu JP, Lin JR, Hsieh E. A noninferiority test for treatment-by-factor interaction with application to 
bridging studies and global trials. Drug Information Journal. 2009; 43:11–16.
Ministry of Health, Labour and Welfare of Japan. Basic Principles on Global Clinical Trials. Tokyo, 
Japan: Pharmaceuticals and Medical Devices Agency; 2007. 
Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Zhang K, et 
al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type kras exon 2 
metastatic colorectal cancer (aspecct): A randomised, multicentre, open-label, non-inferiority 
phase 3 study. The Lancet Oncology. 2014; 15:569–579. [PubMed: 24739896] 
Quan H, Li M, Chen J, Gallo P, Binkowitz B, Ibia E, Tanaka Y, Ouyang SP, Luo X, Li G, et al. 
Assessment of consistency of treatment effects in multiregional clinical trials. Drug Information 
Journal. 2010; 44:617–632.
Quan H, Li M, Shih WJ, Ouyang SP, Chen J, Zhang J, Zhao PL. Empirical shrinkage estimator for 
consistency assessment of treatment effects in multi-regional clinical trials. Statistics in Medicine. 
2013; 32:1691–1706. [PubMed: 22855311] 
Quan H, Shih WJ. Treatment by stratum interaction test for equivalence and non-inferiority trials. 
Proceedings of the Biopharm Section, Joint Stat. Meetings, Am Stat Assoc., CD Version, ASA. 
2002
R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R 
Foundation for Statistical Computing; 2013. 
Shih, WJ., Quan, H. Consistency of treatment effects in bridging studies and global multiregional 
trials. In: Liu, J-pChow, S-C., Hsiao, C-F., editors. Design and Analysis of Bridging Studies. Boca 
Raton, FL: CRC Press; 2013. 
Tsong, Y., Tsou, HH. Multiregional clinical trials. In: Liu, J-pChow, S-C., Hsiao, C-F., editors. Design 
and Analysis of Bridging Studies. Boca Raton, FL: CRC Press; 2013. 
Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, 
Maurel J, Richardson G, et al. Open-label phase III trial of panitumumab plus best supportive care 
compared with best supportive care alone in patients with chemotherapy-refractory metastatic 
colorectal cancer. Journal of Clinical Oncology. 2007; 25:1658–1664. [PubMed: 17470858] 
Wiens BL, Heyse JF. Testing for interaction in studies of noninferiority. Journal of Biopharmaceutical 
Statistics. 2003; 13:103–115. [PubMed: 12635906] 
Diao et al. Page 12
J Biopharm Stat. Author manuscript; available in PMC 2018 March 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Sizes and powers for testing H0b with N = 575. Solid and dashed curves correspond to the 
sizes and powers of the signed likelihood ratio test using the MLEs and the REML 
estimators, respectively. Black, blue, red, and green curves correspond to the sizes and 
powers when σ = 0.1345, 0.269, 0.4035, and 0.538, respectively. The null values of β for 
, and  are 0.0368, −0.0764, −0.1896, and −0.3028, respectively.
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Figure 2. 
Powers for testing H0b with β = −0.416. —-, ; —-, ;, ; —-, . 
Sample size of N = 1150 corresponds to the sample size in the real data.
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Figure 3. 
Sizes and powers for testing H0b with N = 1150 under different allocation rules.
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Figure 4. 
Histogram and normal Q–Q plot of .
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Table 2
p-Values for testing H0b : P(βl ≤ M) = p.
M p p-value (MLE) p-value (REML)
0.151 0.50 0.019 0.021
0.70 0.246 0.273
0.75 0.371 0.406
0.80 0.516 0.556
0.85 0.666 0.706
0.90 0.803 0.835
0.201 0.50 0.006 0.007
0.70 0.135 0.155
0.75 0.229 0.259
0.80 0.357 0.397
0.85 0.513 0.558
0.90 0.681 0.725
0.251 0.50 0.002 0.002
0.70 0.068 0.081
0.75 0.130 0.153
0.80 0.228 0.262
0.85 0.367 0.412
0.90 0.545 0.595
0.301 0.50 0.001 0.001
0.70 0.032 0.040
0.75 0.069 0.084
0.80 0.135 0.162
0.85 0.246 0.285
0.90 0.411 0.462
Note. Testing of H0b for p = 0.5 corresponds to the testing of the overall treatment effect because ϕ−1(0.5) = 0.
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